Please find information on the IPO of Marinomed Biotech AG below.

Company: Marinomed Biotech AG
Symbol: MARI
Trading Segment: Official Market
Market Segment: prime market
Category: no-par value bearer shares
Number of Shares (before IPO): 1,000,000 ordinary shares
Share Capital (before IPO): EUR 1,000,000.--
First Day of Trading: 1 February 2019
Offered Shares:
up to 260,000 shares
up to 40,000 shares (upsize option)
up to 45,000 shares (greenshoe)
Offering Period: scheduled from 24 January 2019 until 29 January 2019
Price Fixing: 29 January 2019
Price Range: EUR 75.-- to EUR 90.--
Offer Price: EUR 75,--
Issuing Volume: EUR 19.5 million excl. greenshoe
Sole Global Coordinators, Underwriter and Sole Bookrunners: Erste Group Bank AG
Manager: goetzpartners securities Limited
Management Board:
Andreas Grassauer
Eva Prieschl-Grassauer
Pascal Schmidt
Supervisory Board:
Simon Nebel
Ute Lassnig
Karl Lankmayr
Gernot Hofer
Brigitte Ederer
Shareholder Structure (before IPO):
Acropora Beteiligungs GmbH - 33.29%
Hermann Unger - 13.03%
Andreas Grassauer - 12.78%
Eva Prieschl-Grassauer - 12.78%
Invest Unternehmensbeteiligungs
Aktiengesellschaft - 10.29%
aws Mittelstandsfonds Beteiligungs
GmbH & Co KG - 10.00%
VETWIDI Forschungsholding GmbH - 3.96%
Pascal Schmidt - 2.00%
Helmut Baranyovszki - 0.87%
Martin Platzer - 0.50%
Angelika Bodenteich - 0.49%
Total 100%
Veterinärplatz 1
1210 Vienna
T +43 (0)1 250774460

About Marinomed Biotech AG

(Profile provided by the company)

Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners.

The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at


This website contains forward-looking statements and forecasts based on assumptions and expectations current at the time of publication. These forward-looking statements involve risks and uncertainties, and therefore, actual developments or events may turn out to be completely different from those expressed or implied by such statements. Forward-looking statements should not be understood as a guarantee of future developments or events, nor should readers place undue reliance on such statements. Wiener Börse AG does not assume any liability whatsoever for the forward-looking statements or forecasts, and actual events may differ materially from those expressed in these forward-looking statements or forecasts. The forward-looking statements in this press release are based on assumptions and expectations current at the time of publication and will not be updated at a later time. None of the information or statements on this website may be construed as a solicitation to buy or a recommendation to invest by Wiener Börse AG and neither can such information or statements serve as a basis for investment decisions in any country or for any person.